Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Pediatric soft tissue sarcomas

L H Wexler1, L J Helman

  • 1Solid Tumor Section, National Cancer Institute, Bethesda, Maryland.

CA: a Cancer Journal for Clinicians
|July 1, 1994
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Patient-derived xenografts effectively capture responses to oncology therapy in a heterogeneous cohort of patients with solid tumors.

Annals of oncology : official journal of the European Society for Medical Oncology·2017
Same author

A case report of concurrent embryonal rhabdomyosarcoma and diffuse large B-cell lymphoma in an adult without identifiable cancer predisposition.

Biomarker research·2017
Same author

Downregulation of IGFBP2 is associated with resistance to IGF1R therapy in rhabdomyosarcoma.

Oncogene·2013
Same author

Loss-of-function screen in rhabdomyosarcoma identifies CRKL-YES as a critical signal for tumor growth.

Oncogene·2013
Same author

Global methylation analysis identifies PITX2 as an upstream regulator of the androgen receptor and IGF-I receptor genes in prostate cancer.

Hormone and metabolic research = Hormon- und Stoffwechselforschung = Hormones et metabolisme·2012
Same author

Insulin-like growth factor 1 receptor antibody induces rhabdomyosarcoma cell death via a process involving AKT and Bcl-x(L).

Oncogene·2010
Same journal

Serious mental illness and cancer: A call to action for equitable care.

CA: a cancer journal for clinicians·2026
Same journal

Extranodal natural killer/T-cell lymphoma: From fatal to curable.

CA: a cancer journal for clinicians·2026
Same journal

Data support longer recurrence-free survival with nivolumab than with ipilimumab for stage III or IV melanoma.

CA: a cancer journal for clinicians·2026
Same journal

Study finds ovarian cancer survivors who are BRCA carriers have a relatively low risk of breast cancer.

CA: a cancer journal for clinicians·2026
Same journal

Radiation therapy, cytogenetic prognostication, novel systemic chemotherapy, and patient perspective in an adult with choroidal melanoma.

CA: a cancer journal for clinicians·2026
Same journal

Systemic amyloid light-chain amyloidosis beyond ANDROMEDA: Diagnostic challenges and therapeutic updates.

CA: a cancer journal for clinicians·2026
See all related articles

Pediatric soft tissue sarcomas are common childhood cancers. Advances in treatment are improving cure rates, particularly for rhabdomyosarcoma, with ongoing research for better outcomes.

Area of Science:

  • Pediatric oncology
  • Cancer biology
  • Clinical research

Background:

  • Soft tissue sarcomas represent 7% of childhood cancers, ranking sixth in incidence.
  • Rhabdomyosarcoma is the most frequent type of pediatric soft tissue sarcoma.
  • Treatment advancements have improved survival rates for these pediatric neoplasms.

Purpose of the Study:

  • To provide a comprehensive overview of pediatric soft tissue sarcomas.
  • To discuss the fundamental biology of these tumors.
  • To outline current clinical management strategies and ongoing research.

Main Methods:

  • Review of existing literature on pediatric soft tissue sarcomas.
  • Synthesis of information on tumor biology, diagnosis, and treatment.

Related Experiment Videos

  • Analysis of clinical trial outcomes and research trends.

    • Main Results:

    • Multimodality treatment protocols have significantly increased cure rates.
    • Rhabdomyosarcoma shows notable improvements in treatment efficacy.
    • Ongoing research focuses on refining therapies and understanding tumor behavior.

    Conclusions:

    • Pediatric soft tissue sarcomas require intensive, multidisciplinary care.
    • Continued research is crucial for further enhancing cure rates and patient outcomes.
    • Understanding the biology is key to developing targeted therapies.